ARQT
Arcutis Biotherapeutics, Inc.
Latest Form 4:Sale$956KbyCurran Terrie (Director) · filed Aug 28, 2026
Arcutis Biotherapeutics, Inc. (ARQT) has 68 SEC Form 4 filings (127 transaction rows) in the rolling window, disclosed by 11 distinct insiders. Most recent filing: Aug 28, 2026.
The most active filer is See Remarks Burnett Patrick with 15 filings. Insiders have net sold $5.6M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Todd Franklin Watanabe
- Employees:354
- HQ:Westlake Village, CA, US
- IPO:2020-01-31
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$17.8M
reported sales (SEC code S)
Unique Insiders
11
in the rolling window
Market Cap
$3.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 38,200 | $956K | Aug 28 | SEC ↗ | |
Curran TerrieFirst filing | Director | Sale | 1,072 | $28K | Aug 24 | SEC ↗ |
| See Remarks | Sale | 1,697 | $46K | Aug 21 | SEC ↗ | |
| Director | Sale | 4,730 | $124K | Aug 19 | SEC ↗ | |
| See Remarks | Sale | 8,300 | $220K | Aug 14 | SEC ↗ | |
| See Remarks | Sale | 6,700 | $175K | Aug 14 | SEC ↗ | |
| See Remarks | Sale | 955 | $25K | Aug 6 | SEC ↗ | |
Matsuda MasaruFirst in 3 months | See Remarks | Sale | 1,230 | $32K | Aug 6 | SEC ↗ |
Watanabe ToddFirst in 3 months | See Remarks | Sale | 4,375 | $114K | Aug 6 | SEC ↗ |
| Director | Sale | 4,730 | $127K | Jul 17 | SEC ↗ | |
LIN SUE-JEANFirst in 7 months | Director | Sale | 4,946 | $121K | Jun 18 | SEC ↗ |
| Director | Sale | 4,096 | $100K | Jun 18 | SEC ↗ | |
| Director | Sale | 635 | $16K | Jun 18 | SEC ↗ | |
| SVP Chief Financial Officer | Sale | 435 | $9K | May 13 | SEC ↗ | |
| See Remarks | Sale | 222 | $5K | May 13 | SEC ↗ | |
| See Remarks | Sale | 8,256 | $192K | May 6 | SEC ↗ | |
| See Remarks | Sale | 684 | $16K | May 6 | SEC ↗ | |
| SVP Chief Financial Officer | Sale | 1,341 | $32K | May 6 | SEC ↗ | |
| See Remarks | Sale | 3,172 | $75K | May 6 | SEC ↗ | |
| Director | Sale | 7,144 | $164K | May 6 | SEC ↗ | |
| Director | Sale | 10,000 | $239K | Apr 3 | SEC ↗ | |
Leonard Keith RFirst filing | Director | Sale | 39,272 | $997K | Mar 4 | SEC ↗ |
| Director | Sale | 10,000 | $257K | Mar 4 | SEC ↗ | |
| See Remarks | Sale | 3,325 | $93K | Mar 3 | SEC ↗ | |
| See Remarks | Sale | 8,733 | $221K | Mar 3 | SEC ↗ | |
| See Remarks | Sale | 3,687 | $93K | Mar 3 | SEC ↗ | |
| See Remarks | Sale | 6,287 | $158K | Mar 3 | SEC ↗ | |
| SVP Chief Financial Officer | Sale | 2,853 | $72K | Mar 3 | SEC ↗ | |
| See Remarks | Sale | 37,349 | $941K | Mar 3 | SEC ↗ | |
| See Remarks | Sale | 40,638 | $1.0M | Feb 4 | SEC ↗ | |
| See Remarks | Sale | 3,675 | $94K | Feb 4 | SEC ↗ | |
| See Remarks | Sale | 9,794 | $253K | Feb 4 | SEC ↗ | |
| See Remarks | Sale | 2,052 | $52K | Feb 4 | SEC ↗ | |
| Director | Sale | 10,000 | $250K | Feb 4 | SEC ↗ | |
Vairavan LathaFirst in 3 months | SVP Chief Financial Officer | Sale | 1,320 | $34K | Feb 4 | SEC ↗ |
| See Remarks | Sale | 19,833 | $506K | Feb 4 | SEC ↗ | |
| See Remarks | Sale | 2,490 | $72K | Jan 7 | SEC ↗ | |
| Director | Sale | 10,000 | $290K | Jan 6 | SEC ↗ | |
| See Remarks | Sale | 1,697 | $50K | Jan 2 | SEC ↗ | |
| See Remarks | Sale | 11,500 | $333K | Dec 17 | SEC ↗ | |
| See Remarks | Sale | 1,657 | $50K | Dec 3 | SEC ↗ | |
| Director | Sale | 10,000 | $302K | Dec 3 | SEC ↗ | |
LIN SUE-JEANFirst filing | Director | Sale | 25,272 | $778K | Nov 25 | SEC ↗ |
| See Remarks | Sale | 1,055 | $32K | Nov 24 | SEC ↗ | |
| See Remarks | Sale | 48,945 | $1.5M | Nov 24 | SEC ↗ | |
| See Remarks | Sale | 2,550 | $72K | Nov 21 | SEC ↗ | |
Gilbert Halley EFirst filing | Director | Sale | 16,532 | $455K | Nov 21 | SEC ↗ |
Krishnamohan NehaFirst filing | Director | Sale | 40,504 | $939K | Nov 17 | SEC ↗ |
| See Remarks | Sale | 17,250 | $417K | Nov 10 | SEC ↗ | |
| See Remarks | Sale | 29,131 | $733K | Nov 10 | SEC ↗ | |
Burnett PatrickFirst filing | See Remarks | Sale | 2,622 | $65K | Nov 5 | SEC ↗ |
Burnett PatrickFirst filing | See Remarks | Sale | 3,864 | $92K | Nov 5 | SEC ↗ |
| See Remarks | Sale | 7,208 | $178K | Nov 5 | SEC ↗ | |
| See Remarks | Sale | 11,547 | $285K | Nov 5 | SEC ↗ | |
| Director | Sale | 10,000 | $253K | Nov 5 | SEC ↗ | |
Vairavan LathaFirst filing | SVP Chief Financial Officer | Sale | 88 | $2K | Nov 5 | SEC ↗ |
| See Remarks | Sale | 40,000 | $1.0M | Oct 30 | SEC ↗ | |
Edwards Larry ToddFirst filing | See Remarks | Sale | 4,504 | $90K | Oct 6 | SEC ↗ |
| Director | Sale | 10,000 | $189K | Oct 3 | SEC ↗ | |
| See Remarks | Sale | 24,261 | $469K | Oct 3 | SEC ↗ | |
| See Remarks | Sale | 20,739 | $416K | Oct 3 | SEC ↗ | |
Watanabe ToddFirst filing | See Remarks | Sale | 9,625 | $169K | Sep 10 | SEC ↗ |
Watanabe ToddFirst filing | See Remarks | Sale | 504 | $9K | Sep 10 | SEC ↗ |
Matsuda MasaruFirst filing | See Remarks | Sale | 36,130 | $584K | Sep 8 | SEC ↗ |
Welgus Howard G.First filing | Director | Sale | 10,000 | $156K | Sep 4 | SEC ↗ |
Congress trading ARQT
See timeline →- DRep. Gilbert CisnerosPurchase$1,001 - $15,0002026-05-29
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Related companies
Arcutis Biotherapeutics, Inc. is in the Healthcare sector.